Ближайший уровень поддержки по SPY – 200.80 уровень сопротивления – 201.20
Gapping up/down: DGLY +15% after guidance, CPWR +15%, FLWS 13%, and TMUS+3% on M&A news, TSLA +3% on upgrade; CONN -25% after earnings, metals and miners trading lower, OSIS -3% after dg
In reaction to strong earnings/guidance: DGLY +15.5%, FORM +2.4%, KFX +1.1%, (also announces acquisition of Softpro GmbH) ZNH +1%, GZT +0.7%.
M&A news: CPWR +15% (WSJ reporting that company is in sale discussions), FLWS +12.6% (signs definitive agreement to acquire Harry & David Holdings for $142.5 mln in cash), TMUS +2.8% (Illiad (ILIAY) in discussions with buyout firms regarding TMUS bid, according to reports), DG +1.7% (to raise bid for FDO for $80/share), TSL +1.4% (acquires Majority Stake in Yunnan Metallurgical New Energy), ARCP +0.8% (confirms Cole Corporate Income Trust entered into merger agreement relating to the sale of CCIT to Select Income REIT (SIR)), FDO +0.6% (Dollar General (DG) confirms enhanced proposal to acquire Family Dollar).
Select pharma/biotech related names showing strength: ELOS +10.5%, ZGNX +5.9% (reports that Zohydro ER demonstrates sustained 12-hour pain relief), ARNA +3.9%, NVS +3.5% (new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial, early results of upcoming presentations).
Other news: HGSH +43.2% (signed its second shanty area rebuilding project agreement with a budgeted investment over $750 mln), ASTI +21.2% (announces new common stock investment of $8.0 mln led by largest shareholder), SYNA +4.7% (positive Barron’s mention), USG +3.5% (positive Barron’s mention), ISNS +2.4% (in sympathy with DGLY), NXPI +2.2% (reports that Apple (AAPL) may partner with Visa (envy) and Mastercard (MA) for payment applications), DTV +1.9% (still checking), OWW +1.8% (reaches an agreement with American Airlines (AAL) to continue to offer American Airlines and US Airways (LCC) flights on all of its sites), BLDP +1.8% (appoints Randy MacEwen as President and Chief Executive Officer, effective October 6, 2014), PBA +1.2% (to acquire the Vantage pipeline system and Mistral Midstream’s interest in the Saskatchewan Ethane Extraction Plant), NBG +0.9% (still checking), YHOO +0.8% (Alibaba.com to begin roadshow next week, according to reports).
Analyst comments: SPLS +4.9% (upgraded to Outperform from Neutral at Credit Suisse), SD +3.4% (upgraded to Buy at Stifel), CENX +3% (upgraded to Overweight from Equal-Weight at Morgan Stanley), GRPN +2.9% (upgraded to Sector Perform at RBC Capital Mkts), STO +2.9% (upgraded to Buy from Hold at Deutsche Bank), TSLA +2.9% (upgraded to Buy from Hold at Stifel), DSKY +2.6% (initiated with a Overweight at Piper Jaffray), ACHN +2.6% (tgt raised to $15 from $11 at UBS), TS +2.4% (upgraded to Neutral from Sell), RCAP +1.9% (upgraded to Buy from Neutral at Citigroup), ZU +1.5% (upgraded to Buy from Fair Value at CRT Capital), ANET +1.3% (initiated with a Buy at Sun Trust Rbsn Humphrey), COG +1% (upgraded to Buy at Stifel), AAPL +0.8% (target raised to $120 from $105 at Piper Jaffray)
In reaction to disappointing earnings/guidance: CONN -25.5%, VIVO -0.6%.
Select pharma/biotechl related names showing weakness: AMPE -5.1% (announces update on the phase III, multicenter, double-blind STEP study of Ampion for osteoarthritis of the knee), GSK -1.6%, AZN -1.1%.
Select metals/mining stocks trading lower: GFI -2.5%, PAAS -2.4%, NEM -2.1%, GG -2%, GDX -1.8%, SLV -1.7%, GOLD -1.7%, GLD -1.6%, SLW -1.4%, .
Other news: EXEL -52.4% (announces results from the COMET-1 Phase 3 pivotal trial of Cabozantinib in men with metastatic castration-resistant prostate cancer), RIBT -17.4% (disclosed its Irgovel plant experienced a structural breakdown; co withdraws prior guidance), TWGP -11.9% (received a letter from the SEC stating that the SEC is conducting an investigation and attaching a subpoena for various documents), PT -2.7% (still checking), LXRX -1.3% (files for $150 mln mixed securities shelf offering), PXLW -1.2% (files $50 mln common stock shelf offering), HSBC -0.9% (stake sold by Fund Manager Neil Woodford, according to reports), CREE -0.7% (LED demand fell in Q3 QoQ, according to reports (not stock specific)).
Analyst comments: OSIS -3.1% (downgraded to Perform from Outperform at Oppenheimer), FNSR -2.5% (downgraded to Hold from Buy at Jefferies), EMES -1.7% (downgraded to Neutral at Robert W. Baird on valuation), FCX -0.5% (downgraded to Equal-Weight from Overweight).GT_support Новости фондового рынка и Торговые идеи
Ближайший уровень поддержки по SPY – 200.50 уровень сопротивления – 200.85
EMES покупка выше 141
SLCA покупка выше 71.50
MNK покупка выше 80.50
BOBE смотрим на откат вверх
Gapping up/down: SPLK +7% and RALY +6% after eranings, CRTO +21% on M&A spec, TSLA +2% on deal with CHU, SSYS +1.5% after Buy initiation; ZOES -1% on earnings, GOMO -1% after dg at CS
In reaction to strong earnings/guidance: UEPS +17.9%, VEEV +12.2%, SPLK +6.7%, RALY +6.4%, ANFI +5.4%, AVGO +5.3%, PSUN +4.3%, BONA +3.9%, FRED +2.9%, CO +2.3%, OVTI +2.3%.
M&A news: CRTO +20.7% (may be attributed to Publicis (PUBGY) speculation), AZN +2.2% (reports that Pfizer (PFE) and AZN may have resumed merger talks), .
Select Biotech related names showing strength: FOLD +5.2%, AEZS +3.6%, KERX +0.7%, ACHN +0.5%.
Other news: DGLY +7.1% (continue momentum higher), BCRX +4.1% (receives additional NIAID funding to conduct a non-human primate study of BCX4430 in Ebola virus disease), RSH +3.5% (cont strength), CHU +3.4% (agreement with Tesla for charging stations), NXPI +3% (Apple and NXP Semi (NXPI) working on payment system technology for iPhone, according to reports), KNDI +2.1% (China considering new tax on gasoline to help electric car market, according to reports), TSLA +1.7% (has agreed to deal with China Unicom (CHU) for charging stations, according to reports)
Analyst comments: SSYS +1.5% (initiated with a Buy at Stifel), CRH +1.1% (upgraded to Buy from Neutral at Goldman)
In reaction to disappointing earnings/guidance: ZOES -1.3%, BIG -0.5%
Select Russia related names showing weakness (Russian stocks downgraded at Morgan Stanley): MBT -3.8% (also dg’d at DB, see below), RSX -1.3%, VIP -1%, YNDX -0.9%.
Other news: ISNS -6.6% (may be related to large shareholder selling shares), FRO -2.2% (cont weakness), NOAH -1.2% (still checking), MCHP -0.6% (co confirmed it is in preliminary discussions with CSR plc).
Analyst comments: MBT -3.8% (downgraded to Hold from Buy at Deutsche Bank), GOMO -1.2% (downgraded to Neutral from Outperform at Credit Suisse).GT_support Новости фондового рынка и Торговые идеи
Ближайший уровень поддержки по SPY – 199.45 уровень сопротивления – 200.00
HUM продажа ниже 127
BITA продажа ниже 88
ATHM продажа ниже 50
QIHU продажа ниже 88
GMCR продажа ниже 134
Gapping up/down: SIG +3% after earnings, DGLY +14% after new order announcement, RPRX +12% after study results, FEYE +2% after initiation w/Buy; GOMO-22%, GES -8.3% and ANF -6% after earnings, GTAT -2% after dg
In reaction to strong earnings/guidance: EDAP +4.2%, SIG +2.7%, VNET +2%, DATE +1.8%, LCI +1.7%, WDAY +1.3%.
Select metals/mining stocks trading higher: GFI +2.2%, SLV +1.7%, HL +1.6%, GG +1.4%, IAG +1.3%, AEM +1.3%, SLW +1.3%, ABX +1.3%, AUY +1.3%, GOLD +0.8%.
Other news: CREG +24.5% (Chairman Guohua Ku has entered into a share purchase agreement to purchase ~13.83 mln shares at $1.37/share), DGLY +13.8% (receives order from State Police Of Michigan valued at more than $1.1 mln), ETRM +13.1% (announces three year diabetes, hypertension and weight loss data from the Maestro RC system DM2 ENABLE study), RPRX +12.6% (achieves superiority in top line analysis for both co-primary endpoints and various secondary endpoints versus marketed topical gel in first of two identical studies in the treatment of secondary hypogonadism), TKMR +9.4% (story suggesting it is a takeover candidate; lists GlaxoSmithKline (GSK) and Shire (SHPG) as interested parties), SYN +8.1% (Co and FUJIFILM Diosynth Biotechnologies UK announce significant improvement in API manufacturing of SYN-004 for the prevention of C. difficile), SCLN +7.5% (and BTG announce that DC Bead has been approved by China FDA ), MRCY +2% (receives $27 mln order for airborne sensor processing application; follows $39 mln missile defense radar subsystems order received last quarter ), WOOF +1.7% (announces new $1.4 billion credit facility and share repurchase authorization of up to $400 million), AVIV +1.7% (to join the S&P SmallCap 600), CNC +1.5% (to join the S&P MidCap 400)
Analyst comments: FEYE +1.7% (initiated with a Buy at Stifel), CRH +1.5% (upgraded to Outperform from Underperform at Credit Suisse), PANW +0.9% (resumed with a Buy at Stifel), FHN +0.8% (upgraded to Outperform from Mkt Perform at Keefe Bruyette), GOLD +0.8% (upgraded to Neutral from Underweight at HSBC Securities), SMTC +0.8% (resumed with a Buy at Goldman)
In reaction to disappointing earnings/guidance: GOMO -21.8%, WSM -10.5%, TLYS -9.6%, FRO -8.9%, GES -8.3%, GCO -6.5%, ANF -6.1%, GMAN -5.8%, HSOL -5.5%, VE -1.7%, VMEM -1.2%, .
M&A news: TEF -0.8% (raises bid offer for Vivendi’s (VIVHY) GVT unit).
Select EU financial related names showing weakness: DB -2.1%, SAN -1.7%, UBS -0.8%
Select metals/mining stocks trading lower after Austrian steelmaker Voestalpine AG sees drop in iron ore prices due to over supply: RIO -3.6%, MT -2.1%, BHP -1.9%, CLF -1.9%.
Select Biotech related names showing early weakness: ISNS -4.2%, FOLD -3.1%, MACK -1.8%, ARWR -1.8%, ACHN -1.5%, ARIA -1.1%
Other news: ROX -7.3% ((filed for $30 mln mixed securities shelf offering), TIF -0.5% (filed mixed securities shelf offering),), RSH -3.7% (pulling back from yesterday’s 20% gain), FOLD -3.1% (still checking), RSX -3.1% (new reports of Russian invasion into Ukraine), AEO -2.3% (in sympathy with ANF), RH -2% (following WSM results), YNDX -1.8% (Russian exposure).
Analyst comments: GTAT -2.2% (downgraded to Underperform from Mkt Perform at Raymond James), NOK -2% (removed from Europe 1 List at BofA/Merrill ), HTZ(e) -1.2% (heaing estimates cut at MS), V -0.8% (downgraded to Mkt Perform from Outperform at Raymond James)GT_support Новости фондового рынка и Торговые идеи
Ближайший уровень поддержки по SPY – 200.30 уровень сопротивления – 200.60
AMGN смотрим на покупку выше 137
CMCM смотрим за ним
Gapping up/down: EXPR +14% and ARUN +8% after earnings, MNKD +4% after initiation with Buy at Jefferies; SWHC -11% and TIVO -2% after earnings, LEJU -4% after dg at GS
In reaction to strong earnings/guidance: TUBE +32.5%, EXPR +13.9%, ARUN +8%, DCI +5.7%, NMBL +2.9%, TIF +2.7%, HEI +2.3%, REX +1.8%, BWS +1.4%
M&A news: OIBR +1.8% (Engagement of Banco BTG Pactual to act as agent to review alternatives to the acquisition of the shares of TIM)
Other news: ISNS +25.9% (seeing continued strength — another recent security play, ie DGLY, TASR), AEGR +8.2% (announces resolution of warning letter for JUXTAPID (lomitapide) capsules), PKT +6.9% (receives $5 mln in initial orders from Tier 1 European MSO), ALTV +5.4% (following late move higher on Juniper Investment Company amended 13D filing with proposal for an all-cash acquisition of $8/share), RSH +4.7% (continued strength following yesterday’s rumors on potential financing), RYAAY +3.6% (launched Ryanair Business Plus), PT +3.5% (still checking), CLUB +3.4% (Farallon Capital files amended 13D; indicates company should be prepared to evaluate potential acquirers’ interest and engage financial advisor ), YOKU +3.3% (announces up to $300 mln share repurchase program), HZNP +2.5% (announces the USPTO issuance of an additional notice of allowance with claims covering RAYOS delayed-release tablets), ARO +2.1% (in sympathy with EXPR), MBLY +1.9% (cont strength), GALE +1.7% (still checking), KLIC +1.7% (authorized the repurchase of up to $100 mln of co’s common shares), TRNS +1.4% (co increased secured revolving credit facility to $30 mln, up from $20 mln; $15 mln now available for acquisitions, up from previous $10 mln), ALLT +1.2% (in sympathy with PKT (closest peer)), DGLY +1.2% (cont momentum), BRCM +1.2% (Netatmo has selected the Broadcom Wireless Internet Connectivity for Embedded Devices Wi-Fi technology), LGND +1% (partner GSK receives FDA approval for Promacta/Revolade for use in patients with severe aplastic anemia), GSK +1% (receives FDA approval for Promacta/Revolade for use in patients with severe aplastic anemia), STJ +0.9% (resolves FDA Warning Letter for Plano Facility)
Analyst comments: ACLS +9.4% (initiated with a Buy at Stifel), MNKD +3.7% (initiated with a Buy at Jefferies), RCII +2.9% (upgraded to Buy from Hold at Canaccord Genuity), HTH +2.3% (upgraded to Outperform from Mkt Perform at Keefe Bruyette), TTI +1.8% (upgraded to Outperform at Cowen), LVLT +1.3% (upgraded to Outperform from Neutral at Macquarie)
In reaction to disappointing earnings/guidance: SWHC -11.1%, DAEG -10.9%, YGE -4.8%, CHS -4.7%, SDRL -4.2%, TIVO -2.2%, (announces new $350 mln share repurchase plan), SLH -1.6%, BMRN -1.3%, (adjusted guidance to reflect one-time sale item), DY -1.2%, BF.B -0.8%
M&A news: COV -1.5% (investor has filed lawsuit to block Medtronic (MDT) deal, according to reports)
Other news: TLM -4.1% (seeing reports that co’s discussions with Repsol (REPYY) regarding a potential deal for the sale of assets have stalled), RGR -3.5% (following SWHC results), AR -0.8% (co raised its production guidance and 2014 capital budget to $3.7 bln), OWW -0.5% (OWW issues statement regarding American Airlines action; Orbitz for Business is not impacted)
Analyst comments: LEJU -4.4% (downgraded to Neutral from Buy at Goldman), RGR -3.5% (downgraded to Fair Value from Buy at CRT Capital, also in sympathy with SWHC), EJ -2.7% (downgraded to Neutral from Buy at Goldman), FB -0.5% (downgraded to Neutral from Buy at Janney)
GT_support Новости фондового рынка и Торговые идеи
Ближайший уровень поддержки по SPY – 200.25 уровень сопротивления – 200.45
BITA продажа от 92
ATHM покупка на продолжение тренда вверх после 56
CONN покупка выше 46
In reaction to strong earnings/guidance: DSW +11.7%, PINC +2.1%, DAKT +0.9%.
M&A news: THI +11.8% (Tim Hortons shareholders will receive C$65.50 in cash and 0.8025 common shares of the new company per Tim Hortons share from BKW), BKW +4.2% (also, Warren Buffet (BRK.B) plans to invest in Tim Horton’s (THI) & BKW deal, according to reports).
Select pharma/biotech related names showing strength: BABY +13%, ENZN +5.2%, IDRA +4.9%, DNDN +4.5%, PVCT +4.5%, ICPT +3.2%, REGN +1.6%, TKMR +1%, .
Select metals/mining stocks trading higher: IGLD +2%, GDX +1.4%, ABX +1.3%, GFI +1.2%, SLV +1.1%, GOLD +1.1%, AEM +0.9%, KCG +0%, .
Other news: GENE +18.3% (announced earlier further patent success in USA), KITE +16% (announced patients with aggressive non-Hodgkin’s lymphoma experience positive results afte rreceiving anti-CD19 chimeric antigen receptor T Cells; 12 out of 13 evaluable patients had complete remissions or partial remissions), ZGNX +15.4% (Armistice Capital discloses 5.9% passive stake in 13G filing) DGLY +13.2% (following 50%+ move higher yesterday), MNOV +12% (to initiate clinical trial of MN-166 (ibudilast) in ALS ), KNDI +8.8% (China will consider $16 bln in funding for electric vesicles, according to reports ), ACHN +4.5% (cont strength), PE +3.4% (acquired Midland Basin assets for ~$252 mln;), CMTL +2.6% (late spike on reports of potential sale), CMTL +2.6% (confirmed it is exploring strategic alternatives), PINC +2.1% (announced the acquisition of Aperek, Inc. for $48.5 mln in cash; co also reported earnings), PT +1.6% (still checking), AMKR +1.1% (poisitve Mad Money Mention), NEM +1.1% (mining arbitration case against Indonesia has been withdrawn, according to reports).
Analyst comments: MBLY +3.7% (initiated with an Overweight at Barclays, initiated with an Outperform at William Blair, among others), MT +3.2% (upgraded to Buy from Sell at UBS), VE +2.4% (upgraded to Outperform from Neutral at Exane BNP Paribas), ENPH +2.2% (initiated with a Buy at Needham), MPEL +1.6% (upgraded to Overweight from Equal-Weight at Morgan Stanley), PCYC +1.2% (Hearing positive comments at Deutsche Bank related to prospects of Imbruvica)
GT_support Новости фондового рынка и Торговые идеи
Чтобы первыми узнавать последние новости советуем вам подписаться на RSS
- Леонид Сухарев on Книга Фондовый рынок США для начинающих инвесторов скачать pdf epub (Фридом Финанс) скачать
- Статистика по счету для live show | Dаy trading на фондовой бирже США (NYSE, NASDAQ, AMEX - акции) Блог трейдера. Обучение. Инвестиции on Брокеры
- Статистика по счету для live show | Dаy trading на фондовой бирже США (NYSE, NASDAQ, AMEX - акции) Блог трейдера. Обучение. Инвестиции on Трансляция сделок Day Trading на NYSE, NASDAQ – live show
- Игорь Иванов on Книга Фондовый рынок США для начинающих инвесторов скачать pdf epub (Фридом Финанс) скачать
- Трансляция сделок Day Trading на NYSE, NASDAQ — live show | Dаy trading на фондовой бирже США (NYSE, NASDAQ, AMEX - акции) Блог трейдера. Обучение. Инвестиции on NASDAQ – National Association of Securities Dealers Automated Quotation